Avanafil is a PDE5 inhibitor approved for erectile dysfunction by FDA on April 27, 2012 and by EMA on June 21, 2013. Avanafil is known by the trademark names Stendra and Spedra and was developed by Vivus Inc. Avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme which is found in various body tissues, but primarily in the corpus cavernosum penis, as well as the retina.
Sakamoto, Toshiaki; Koga, Yuichi; Hikota, Masataka; Matsuki, Kenji; Murakami, Michino; Kikkawa, Kohei; Fujishige, Kotomi; Kotera, Jun; Omori, Kenji; Morimoto, Hiroshi; Yamada, Koichiro. The discovery of avanafil for the treatment of erectile dysfunction: A novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor. Bioorganic & Medicinal Chemistry Letters. Volume 24. Issue 23. Pages 5460-5465. Journal; Online Computer File. (2014).
Thirumalai, Rajan Srinivasan; Eswaraiah, Sajja; Satyanarayana, Komati. A process for the preparation of chloromethoxybenzylaminohydroxymethylpyrrolidinylpyrimidinylmethylpyrimidine carboxamide. Assignee MSN Laboratories Private Limited, India. IN 2013CH02915. (2015).
Su, Xianbin; Guo, Jiasai; Jin, Kaijun; Dong, Haijun. Solid phase preparation method of avanafil applied in treatment of male erectile dysfunction. Assignee Nanjing University of Technology, Peop. Rep. China. CN 103435599. (2013).
Chen, Lin; Gao, Heyong; Li, Wei. Avanafil intermediate, its preparing method and application. Assignee Angelisun (Chongqing) Pharmaceutical Co., Ltd., Peop. Rep. China. CN 104557877. (2015).
Cui, Zhenwei; Zhang, Weiwei; Zhang, Fuqing. Preparation method of pharmaceutical compound Avanafil. Assignee Chongqing Aoshe Biochemical Co., Ltd., Peop. Rep. China. CN 109280050. (2019).
